Eterna Therapeutics
NASDAQ: ERNACambridge, US · Founded 1994 · Delaware corporation · 8 employees on LinkedIn
Find your way into Eterna Therapeutics
876 people in our graph share verified history with the Eterna Therapeutics team — schools, employers, funds. One of them is your warm intro.
Karthik Ardhanareeswaranunlockedknows Dorothy Clarke · together at Johnson & Johnson (overlapped)
knows the team · via Georgetown
×2knows the team · via Johnson & Johnson
×5knows the team · via Wesleyan University
×2knows the team · via University at Buffalo
knows the team · via New York University School of Law
Eterna Therapeutics develops synthetic allogeneic induced mesenchymal stem cell (iMSC) product candidates for cell therapy applications. The company is in preclinical and clinical development stages, focused on manufacturing and commercializing cell-based therapeutics that require FDA regulatory approval.
Founders & leadership
DC
Dorothy ClarkeinExecutiveDorothy Clarke is General Counsel at Eterna Therapeutics and brings extensive experience in regulatory and compliance law across life sciences, pharmaceuticals, biotechnology, and medical devices, with particular expertise in FDA matters and healthcare compliance.
SG
Sandra GurrolainExecutive
SL
Sanjeev LutherinExecutiveSanjeev Luther is an executive with extensive experience leading clinical-stage biopharmaceutical companies through development and commercialization, including advancing programs through late-stage clinical trials, raising capital, and executing licensing transactions. He has worked across multiple therapeutic areas including oncology, ophthalmology, dermatology, and CNS, and has managed organizations ranging from 10 to 200 employees with budgets up to $500 million.
KD
Kevin D'AmourinChief Scientific Officer
RS
Roger SidhuinChief Medical Officer
HJ
Howard J. FederoffinChief Executive Officer and PresidentHoward J. Federoff holds an MD and PhD from Albert Einstein College of Medicine and has held senior executive roles in higher education and biotech, with expertise in cell and gene therapy, cognitive biomarkers, and advanced biologics for neurodegenerative disease. He is CEO and President of Eterna Therapeutics, which develops synthetic allogeneic induced mesenchymal stem cell product candidates for cell therapy.
JS
Jay SialinChief Administration Officer
ES
Erin S. EnrightinMember Board of Directors2022–2022Managing Partner, Prettybrook Partners LLC at The 98
EM
Erich MohrNamed on SEC filing
CC
Charles CheringtonNamed on SEC filing
DL
Dennis LangerNamed on SEC filing
HB
Heather B. RedmanNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$57.2M disclosed across 8 rounds · 2022–2025
▶$7.2MraisedApr 2025 · 15 investors · BiotechnologyRule 506(b)
▶$7.2MraisedApr 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter CicalaDirector
- Sandra GurrolaExecutive Officer
- William WexlerDirector
- James BristolDirector
- Sanjeev LutherExecutive Officer, Director
- Elena RatnerDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedNov 2024 · 5 investors · BiotechnologyRule 506(b)
▶$1.1MraisedNov 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dorothy ClarkeExecutive Officer, Director
- Sanjeev LutherExecutive Officer, Director
- William WexlerDirector
- Sandra GurrolaExecutive Officer
- James BristolDirector
- Peter CicalaDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.9MraisedNov 2024 · 11 investors · BiotechnologyRule 506(b)
▶$3.9MraisedNov 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dorothy ClarkeExecutive Officer, Director
- William WexlerDirector
- Sandra GurrolaExecutive Officer
- Sanjeev LutherExecutive Officer, Director
- James BristolDirector
- Peter CicalaDirector
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedDec 2023 · 19 investors · BiotechnologyRule 506(b)
▶$7.8MraisedDec 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James BristolDirector
- William WexlerDirector
- Matthew AngelExecutive Officer
- Dorothy ClarkeDirector
- Sandra GurrolaExecutive Officer
- Offering amount
- $9.2M
- Amount sold
- $7.8M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.7MraisedJul 2023 · 19 investors · BiotechnologyRule 506(b)
▶$8.7MraisedJul 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sandra GurrolaExecutive Officer
- Brant BinderDirector
- Richard W. WagnerDirector
- Gregory FioreDirector
- Matthew AngelExecutive Officer, Director
- William WexlerDirector
- Offering amount
- $8.7M
- Amount sold
- $8.7M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.7MraisedJul 2023 · 19 investors · BiotechnologyRule 506(b)
▶$8.7MraisedJul 2023 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew AngelExecutive Officer, Director
- Gregory FioreDirector
- Brant BinderDirector
- Richard W. WagnerDirector
- William WexlerDirector
- Sandra GurrolaExecutive Officer
- Offering amount
- $8.7M
- Amount sold
- $8.7M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.7MraisedDec 2022 · 20 investors · BiotechnologyRule 506(b)
▶$7.7MraisedDec 2022 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew JacksonExecutive Officer
- William WexlerDirector
- Matthew AngelDirector, Executive Officer
- Gregory FioreDirector
- Nicholas J. SingerDirector
- Charles CheringtonDirector
- Sandra GurrolaExecutive Officer
- Roger SidhuExecutive Officer
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$12MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sandra GurrolaExecutive Officer
- Erin S. EnrightDirector
- Kevin D'AmourExecutive Officer
- Roger SidhuExecutive Officer
- Erich MohrDirector
- Charles CheringtonDirector
- Howard J. FederoffExecutive Officer, Director
- Jay SialExecutive Officer
- Dennis LangerDirector
- Heather B. RedmanDirector
- Offering amount
- $12M
- Amount sold
- $12M
- Sales commissions
- $900K
- Placement agents
- Cantor Fitzgerald & Co., Maxim Group LLC
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$7.2Mvaluation at IPOFeb 2026 · $0.92/share · S-1/A
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Eterna Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Eterna Therapeutics do?
- Eterna Therapeutics develops synthetic allogeneic induced mesenchymal stem cell (iMSC) product candidates for cell therapy applications. The company is in preclinical and clinical development stages, focused on manufacturing and commercializing cell-based therapeutics that require FDA regulatory approval.
- How much funding has Eterna Therapeutics raised?
- Eterna Therapeutics has disclosed $57.2M raised across 8 rounds.
- Where is Eterna Therapeutics headquartered?
- Eterna Therapeutics is headquartered in Cambridge, US.